Biosyent Inc
XTSX:RX
Biosyent Inc
Tax Provision
Biosyent Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosyent Inc
XTSX:RX
|
Tax Provision
-CA$3.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-8%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Tax Provision
-$247m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Tax Provision
CA$6.6m
|
CAGR 3-Years
94%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Tax Provision
$14.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Tax Provision
CA$6.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Biosyent Inc
Glance View
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
See Also
What is Biosyent Inc's Tax Provision?
Tax Provision
-3.2m
CAD
Based on the financial report for Sep 30, 2025, Biosyent Inc's Tax Provision amounts to -3.2m CAD.
What is Biosyent Inc's Tax Provision growth rate?
Tax Provision CAGR 10Y
-8%
Over the last year, the Tax Provision growth was -39%. The average annual Tax Provision growth rates for Biosyent Inc have been -13% over the past three years , -15% over the past five years , and -8% over the past ten years .
